Role for hypoxia, hypoxia inducible factor HIF1a and vessel formation in early Rheumatoid Arthritis (RA)

• Conditions: Rheumatoid arthritis; 10003816; 10023213

• Registration Number: NL-OMON31469
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

Patients will have to fulfil the ACR classification criteria for Rheumatoid Arthritis (RA)
The duration of disease should be less than 1 year.
Patients need to have an actively inflamed knee or ankle joint.
There is an indication for treatment with MTX (methotrexate)
No contraindications against MTX treatment

Exclusion Criteria

No RA
Contraindications against MTX

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. To investigate the amount of HIF1a expression and (neo-) angiogenesis in<br /><br>early RA.<br /><br>secondary</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. To explain the difference in HIF1a expression and (neo-) angiogenesis<br /><br>between MTX responders and non-responders according to DAS response criteria.<br /><br>2.To study whether there is a relation between hypoxia, subsequent HIF1a<br /><br>expression and (neo-) angiogenesis and the amount of inflammatory cells. </p><br>